Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology - 1 Jan 2000

Sood Ajit, Midha Vandana, Sood Neena, Bansal Manu

Abstract excerpt

BACKGROUND: The treatment of hepatitis C virus (HCV)-related cirrhosis is difficult due to high frequency of adverse effects. We retrospectively reviewed the case records of patients with HCV cirrhosis to evaluate the efficacy and tolerability of pegylated (peg) interferon and ribavirin treatment in these patients. METHODS: Medical records of 28 patients with HCV-related compensated cirrhosis were reviewed. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 17264426

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.PMID 17264426Read ↗

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.Semantic proximity Read ↗

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].Semantic proximity Read ↗

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Semantic proximity Read ↗

Management of HCV in cirrhosis-a rapidly evolving landscape.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.Semantic proximity Read ↗

A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.Semantic proximity Read ↗

Management of hepatitis C patients with decompensated liver disease.Semantic proximity Read ↗

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.